U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07283991) titled 'QL1706 Plus Chemotherapy for Borderline Resectable Esophageal Cancer' on Nov. 21.
Brief Summary: China bears a disproportionately high burden of esophageal cancer, accounting for approximately 50% of newly diagnosed cases worldwide, with an average 5-year survival rate of only 30%. Esophageal adenocarcinoma and squamous cell carcinoma (ESCC) are the major pathological subtypes, among which squamous cell carcinoma predominates in Asian populations. More than 90% of esophageal cancer cases in China are ESCC.
Optimal treatment for locally advanced esophageal cancer remains a matter of debate. Findings from Japanese clinical studies su...